June 2018 Issue of The Medicine Maker

The cell therapy industry faces a number of complex problems. Fortunately, they’re good problems to have.

Regulators step in to stop stem cell clinics from marketing unproven therapies.

Concerns abound that post-Brexit border delays could turn the UK into a “second tier state for pharmaceutical imports.”

Could artificial intelligence help repurpose old drugs for suffers of the degenerative disorder?

Pharma TV ads are getting longer, less humorous and more nostalgic — while containing fewer facts.

Will President Trump’s prices plan deliver for Americans patients?

A generic and inexpensive way to seperate chiral molecules: magnets

The challenge of convincing senior staff to invest in continuous bioprocessing.

Nominations for the 2018 Innovation Awards are open!

Antibody drug conjugates have not yet lived up to their potential, but there is hope – if we turn to the right solutions and techniques.

Products are becoming increasingly complex and we need to get better at recognizing the strategies with the best advantages.

As we meet increasing demand and satisfy trends towards self-administration in the injectables market, patient safety must remain the primary driver for innovation.

We must find ways to better help vaccine manufacturers to fight the flu – and this is why we developed a new challenge agent for H3N2.

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

mAbs are an important growth area for the biopharma industry – so we need more effective purification technologies.

Even plastic used for biopharma manufacturing can be recycled, if we put our minds to it.

Serialization deadlines will shortly be upon us – but, rather than entering into a blind panic, consider the long term.

Valarie Higgins discusses how clinical trials have evolved over the years and the key lessons she has learned while building her career in the industry.

Sitting Down With... Ajaz Hussain, President, National Institute for Pharmaceutical Technology and Education, Minnesota, USA.

Thanks to the emergence of intensified and connected processes, the path to continuous biopharma manufacturing is open.